Program
befotertinib
Also written as “Befotertinib”, “D-0316” and “D-0316 Capsule”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticals | 42 open or running | phase 3since Dec 10, 2019 | Dec 10, 2019 | Nov 2028phase 2 · NCT07181499 |
| InventisBio | 20 open or running | phase 2since Mar 1, 2019 | Feb 13, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 13, 2018First study: phase 1 study in Advanced Non Small Cell Lung CancerNew to InventisBioInventisBio · NCT03452150 · 84 enrolled · China
- Mar 1, 2019Phase 2 study in Solid TumorInventisBio · NCT03861156 · 290 enrolled · China
- Dec 10, 2019Betta Pharmaceuticals's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT04206072 · 362 enrolled · China
- Jul 3, 2020Phase 1 study in Advanced or Metastatic Non-small Cell LungBetta Pharmaceuticals · NCT04464551 · 4 enrolled · China
- Aug 8, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT05007938 · 30 enrolled · China
- Sep 10, 2025Phase 2 study in NSCLCBetta Pharmaceuticals · NCT07181499 · 28 planned · China
Ahead
- Nov 2028Primary completion: phase 2 study in NSCLCBetta Pharmaceuticals · NCT07181499
TargetBeta
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07181499NSCLC · China | 2 | Recruiting | Betta Pharmaceuticals | Nov 2028 | 28 |
| NCT05007938Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Betta Pharmaceuticals | Dec 31, 2024 | 30 |
| NCT04464551Advanced or Metastatic Non-small Cell Lung · China | 1 | UNKNOWN | Betta Pharmaceuticals | Aug 2021 | 4 |
| NCT04206072Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Betta Pharmaceuticals | Jul 30, 2022 | 362 |
| NCT03861156Solid Tumor · China | 2 | Completed | InventisBio | Aug 15, 2021 | 290 |
| NCT03452150Advanced Non Small Cell Lung Cancer · China | 1 | Completed | InventisBio | Aug 28, 2020 | 84 |
How it is read
Names in the registry
- “Befotertinib”, 2 entries
- “D-0316”, 2 entries
- “D-0316 Capsule”, 1 entry
- “[14C]D-0316 suspension”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.